Navigation Links
Varespladib Receives 2010 European Society Pediatric Research Award
Date:12/7/2010

es interest for pediatricians from primary care, general pediatric practice and specialty practice with a program for intensive care and general pediatric nursing. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Certain statements contained in this press release that refer to future events are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of A
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
4. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
5. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Decision Resources, one of the world,s leading ... that, over the past 12 months, 25 percent of surveyed ... Germany , Italy , ... ) have been required to change the antiretroviral (ARV) ... to reduce costs. Additionally, more than 40 percent of respondents ...
(Date:6/18/2013)... June 18, 2013 Today, Wall Street ... GILD ), Health Management Associates Inc. (NYSE: ... ), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and ... reports free of charge - including full price targets, industry ... Gilead Sciences, Inc. Research Report On June ...
(Date:6/18/2013)... , June 18, 2013 Apama ... on the development of next-generation atrial fibrillation technologies, ... 8295902 by the US Patent and Trademark Office ... low profile electrode assemblies for use on expandable ... or other surgical procedures. "We are ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... 2011 Data presented at the 47th American Society ... of circulating tumor cells (CTC) as a biomarker for ... first randomized, double-blind, placebo controlled Phase III trial to ...  Biomarkers are of scientific interest as, if validated, they ...
... 3, 2011 Civil penalties amounting to $327,073,700 have ... South Carolina versus Ortho-McNeil-Janssen Pharmaceuticals and Johnson & Johnson, ... on June 3 through a written order. John B. ... White, Smith & Coggins, P.C., a Spartanburg-based law firm, ...
Cached Medicine Technology:Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 2Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 3Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 4Record Breaking $327 Million Verdict Announced in Janssen Case 2
(Date:6/18/2013)... Tarrytown, NY (PRWEB) June 18, 2013 ... simply to grow in size. Quite the opposite. ... and audiology practice-with over 140 expertly trained physicians offering ... communities in 40 locations throughout the Greater New York ... the important circumstances are right. And that includes the ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Sun Buick GMC, ... Family Health Services 20th Annual Golf Tournament on Thursday, June ... The hole-in-one prize is a 2013 Buick Verano and will ... gets a hole-in-one on Irem’s 7th hole. , The MFHS ... format is a four person captain and crew team for ...
(Date:6/18/2013)... have a much different and more complex ... of Texas at Dallas have found that exploiting these ... cancer. , In an article published online May 21 ... researchers compared the metabolic characteristics of non-small-cell lung cancer ... patient. , They found that the cancer cells ...
(Date:6/18/2013)... HOUSTON Researchers have discovered and mapped the signaling ... that, if broken, could cut off cancer cell growth ... scientists at The University of Texas MD Anderson Cancer ... (EGFR), a well-known cancer drug target, and MCM7, a ... in the June issue of Cancer Cell . ...
(Date:6/18/2013)... 2013 The Elizabeth Glaser Pediatric AIDS ... the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) ... new milestones in the global effort to eliminate pediatric ... that as of June 2013, one million babies globally ... Since PEPFAR’s inception in 2003, EGPAF has been a ...
Breaking Medicine News(10 mins):Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3
... ... of prime labels with new site enhancements. The site enhancements provide customers with a ... , ... (PRWEB) August 5, 2009 -- My1Stop.com, the commercial printing superstore, launched upgraded prime label ...
... , , , ... healthcare applications and services will grow at a five-year cumulative annual growth ... according to Wireless Healthcare: Analysis & Forecasts ... research firm Parks Associates predicts the push for ...
... of women in the US are recalled for a second ... most women this can be very stressful. However the use ... be associated with a substantial decrease in recall rate, according ... researchers believe that digital breast tomosynthesis depicts the breast tissue ...
... are a woman who dines with a man, chances are you ... woman. That is one of the findings in a study conducted ... online version of the international journal Appetite . Meredith ... found that what a person chooses to eat at lunch or ...
... Forum for People Performance Management and Measurement white paper ... quality , , NAPERVILLE, Ill., Aug. ... billions of dollars each year in new technology and infrastructure to ... be in its people, according to a new white paper published ...
... , , WASHINGTON, Aug. 5 ... latest report on effective emergency management for people with disabilities ... of Emergency Managers, 2009 National Conference on Community ... at the Hyatt Regency Crystal City Hotel, 2799 Jefferson ...
Cached Medicine News:Health News:My1Stop.com Completes Upgrades to Prime Labels Offering and Easy Ordering Page Design 2Health News:Wireless Home Healthcare to be $4 Billion Industry by 2013 2Health News:Wireless Home Healthcare to be $4 Billion Industry by 2013 3Health News:What you eat depends on with whom you eat 2Health News:Happy Employees Lead to Healthier Patients 2Health News:Happy Employees Lead to Healthier Patients 3
... Seat height: Bench high, 26-31". Ergonomic ... "Soft Touch" pnuematic control for easy ... Static-control casters allow easy mobility. Fixed ... Decay (from 5000 Volts to technical ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: